{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:36:59Z","timestamp":1791329819553,"version":"4.3.1"},"reference-count":35,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"34","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with relapsed or refractory chronic lymphocytic leukemia (CLL) have profound immune defects and limited treatment options. Given the dramatic activity of lenalidomide in other B-cell malignancies and its pleotropic immunomodulatory effects, we conducted a phase II trial of this agent in CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients with relapsed or refractory B-cell CLL (B-CLL) were eligible if they required treatment as per the National Cancer Institute Working Group 1996 guidelines. Lenalidomide was administered orally at 25 mg on days 1 through 21 of a 28-day cycle. Response was assessed after each cycle. Patients were to continue treatment until disease progression, unacceptable toxicity, or complete remission. Rituximab was added to lenalidomide on disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-five patients were enrolled, with a median age of 64 years. Sixty-four percent of the patients had Rai stage III or IV disease, and 51% were refractory to fludarabine. The overall response rate was 47%, with 9% of the patients attaining a complete remission. Fatigue, thrombocytopenia, and neutropenia were the most common adverse effects noted in 83%, 78%, and 78% of the patients, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lenalidomide is clinically active in patients with relapsed or refractory B-CLL. These findings are encouraging and warrant further investigation of this agent in the treatment of this disorder.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2005.05.0401","type":"journal-article","created":{"date-parts":[[2006,11,6]],"date-time":"2006-11-06T20:54:30Z","timestamp":1162846470000},"page":"5343-5349","source":"Crossref","is-referenced-by-count":344,"title":["Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study"],"prefix":"10.1200","volume":"24","author":[{"given":"Asher","family":"Chanan-Khan","sequence":"first","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kena C.","family":"Miller","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Musial","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaminathan","family":"Padmanabhan","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Takeshita","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl W.","family":"Porter","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Goodrich","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zale P.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wallace","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spaner","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mohr","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Byrne","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Chrystal","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Starostik","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Pharmacology and Therapeutics, Biostatistics, and Pathology, Roswell Park Cancer Institute, Buffalo, NY; Celgene Corporation, Summit, NJ; and Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.bloodjournal462219"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0796"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1021"},{"key":"R9","unstructured":"Bartik MM, Welker D, Kay NE: Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 25:27,1998-33,"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24176"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.399"},{"key":"R12","unstructured":"Hoffbrand AV, Panayiotidis P, Reittie J, et al: Autocrine and paracrine growth loops in chronic lymphocytic leukemia. Semin Hematol 30:306,1993-317,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.7.2387"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00305.x"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309059568"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4249.bloodjournal84124249"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409051650"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.10.014"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402467"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041668"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2004.n.006"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.09.005"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601579"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0996"},{"key":"R25","unstructured":"Mitsiades CS, Mitsiades N: CC-5013 (Celgene). Curr Opin Investig Drugs 5:635,2004-647,"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2005.01.002"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023143"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.1.192.192"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.265"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602774"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2817"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0669"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Furman R, Leonard J, Allen S, et al: Thalidomide alone or in combination with fludarabine are effective treatments for patients with fludarabine-relapsed and refractory CLL. J Clin Oncol 24:595s,2005,  (suppl; abstr 6640)","DOI":"10.1200\/jco.2005.23.16_suppl.6640"},{"key":"R35","unstructured":"Kay N, Geyer S, Yaqoob I, et al: Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): A North Central Cancer Treatment Group (NCCTG) Study. Blood 102:5162a,2003,  (abstr)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.05.0401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:55:47Z","timestamp":1653497747000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.05.0401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,1]]},"references-count":35,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2006,12,1]]}},"alternative-id":["10.1200\/JCO.2005.05.0401"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.05.0401","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718490090.793497263","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,1]]}}}